AMRN stock news

AMRN earnings call for the period ending September 30, 2019. Read more

Amarin Corporation plc (NASDAQ: AMRN) is having a strong start to the trading session this morning, trading on gains of more than 3%. The gains come after the company reported its quarterly results… Read more

Amarin beats estimates for both earnings and revenues in the third quarter of 2019. Shares up. Read more

AMRN is ripe for downgrades Read more

DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 04, 2019 -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, announced. Read more

Amarin's (AMRN) third-quarter results are likely to reflect strong demand for its cardiovascular drug, Vascepa. Read more

Amarin Corporation plc (AMRN), a pharmaceutical company focused on improving cardiovascular health, today announced that an independent organization that evaluates pricing of prescription drugs has issued its final report assessing the cost-effectiveness of Vascepa® (icosapent ethyl) capsules. The review Read more

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the… Read more

Amarin's stock jumped after SVB Leerink upped its rating on the biotech's stock to outperform, saying a recent double-digit decline offers a buying opportunity….AMRN Read more

Shares of the mid-cap biotech Amarin Corporation plc (NASDAQ: AMRN) were pulling back to their lowest level since early January on Friday. What … Read more

Amarin beats estimates for both earnings and revenues in the second quarter of 2019. Shares up. Read more

Biotech Amarin (AMRN) is one of Wall Street’s biggest standouts, with shares skyrocketing 566% in just the last year. Its fish-oil derivative drug Vascepa is already clinically proven to lower very high triglycerides without raising bad cholesterol. What’s more, recent trials revealed it could also cut Read more

Amarin announces strong preliminary sales of Vascepa in the second quarter. The company increases sales guidance for 2019. Read more

Amarin surges after the pharmaceutical company boosts its revenue guidance amid strong demand for its Vascepa chronic cardiovascular treatment….AMRN Read more

Shares of Amarin Corp. surged 9.2% in premarket trading Tuesday, after the pharmaceutical company raised its full-year revenue outlook and announced plans to… Read more